The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas

Abstract

The role of rituximab in the treatment of B-cell lymphomas has rapidly emerged from the relapsed setting to first-line combination regimens across the broad range of histologic subtypes. The role of maintenance rituximab in indolent lymphomas after first-line therapy needs to be defined along with the integration of radioimmunotherapy into the first-line therapeutic regimens. As mechanisms of action/resistance to monoclonal antibody therapy are better understood, approaches to predicting response and optimizing combination therapy to overcoming primary and acquired resistance may be developed.